Evidence map›Paper›PMID 40109740›Full record

ArticleACS pharmacology & translational science2025

Contilisant-Belinostat Hybrids: Polyfunctionalized Indole Derivatives as Multineurotarget Drugs for the Potential Treatment of Alzheimer's Disease.

Linda Schäker-Hübner, Mireia Toledano-Pinedo, Sophia Eimermacher, Vesa Krasniqi, Alicia Porro-Pérez, Kathrin Tan, Gabriele Horn, Philipp Stegen, Paul W Elsinghorst, Timo Wille and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. PolyfunctionalizedInternational journal of molecular sciences · 2026
    Article
  2. Pharmaceuticals (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Linda Schäker-HübnerPharmaceutical Institute, University of Bonn, An der Immenburg 4, Bonn D-53121, Germany.
Mireia Toledano-PinedoInstitute of General Organic Chemistry (CSIC), C/Juan de la Cierva 3, Madrid 28006, Spain.
Sophia EimermacherFaculty of Applied Natural Sciences, TH Köln-University of Applied Sciences, Campus Leverkusen, Campusplatz 1, Leverkusen D-51379, Germany.ORCID https://orcid.org/0000-0002-2311-3644
Vesa KrasniqiPharmaceutical Institute, University of Bonn, An der Immenburg 4, Bonn D-53121, Germany.
Alicia Porro-PérezInstitute of General Organic Chemistry (CSIC), C/Juan de la Cierva 3, Madrid 28006, Spain.
Kathrin TanPharmaceutical Institute, University of Bonn, An der Immenburg 4, Bonn D-53121, Germany.
Gabriele HornBundeswehr Institute of Pharmacology and Toxicology, Neuherbergstraße 11, München D-80937, Germany.
Philipp StegenPharmaceutical Institute, University of Bonn, An der Immenburg 4, Bonn D-53121, Germany.
Paul W ElsinghorstBundeswehr Medical Academy, Neuherbergstraße 11, München D-80937, Germany.ORCID https://orcid.org/0000-0001-8999-3122
Timo WilleBundeswehr Institute of Pharmacology and Toxicology, Neuherbergstraße 11, München D-80937, Germany.
Markus PietschFaculty of Applied Natural Sciences, TH Köln-University of Applied Sciences, Campus Leverkusen, Campusplatz 1, Leverkusen D-51379, Germany.ORCID https://orcid.org/0000-0002-8110-2265
Michael GütschowPharmaceutical Institute, University of Bonn, An der Immenburg 4, Bonn D-53121, Germany.ORCID https://orcid.org/0000-0002-9376-7897
José Marco-ContellesInstitute of General Organic Chemistry (CSIC), C/Juan de la Cierva 3, Madrid 28006, Spain.ORCID https://orcid.org/0000-0003-0690-0328
Finn K HansenPharmaceutical Institute, University of Bonn, An der Immenburg 4, Bonn D-53121, Germany.ORCID https://orcid.org/0000-0001-9765-5975

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this work, we designed, synthesized, and evaluated two types of multineurotargeting compounds using a pharmacophore merging strategy, aiming to develop potential treatments for Alzheimer's disease. We combined belinostat, an FDA-approved unselective histone deacetylase (HDAC) inhibitor, with the 5-substituted indole core of contilisant, known for its antioxidant and neuroprotective properties as well as its potent inhibitory activity against monoamine oxidases (MAOs), acetylcholinesterase (AChE), and butyrylcholinesterase (BChE). Among these, compounds

Identifiers

PMID40109740
PMCPMC11915037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.